Data Integrity Issues in Bioequivalence Studies

Nilufer Tampal, PhD, Acting Deputy Director of the Office of Bioequivalence, discusses the FDA’s bioequivalence data expectations.
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Phone - [phone] I [phone]